Walter J. Urba
Experienced in Neuroendocrine Tumor

Dr. Walter J. Urba

Oncology
4805 Ne Glisan St, 6n40, 
Portland, OR 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Neuroendocrine Tumor
4805 Ne Glisan St, 6n40, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Walter Urba is an Oncologist in Portland, Oregon. Dr. Urba is rated as an Experienced provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Breast Cancer, and Non-Small Cell Lung Cancer (NSCLC).

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 5 clinical trials in the study of Neuroendocrine Tumor.

Specialties
Oncology
Licenses
Internal Medicine in OR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4805 Ne Glisan St, 6n40, Portland, OR 97213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: MEDI0562
Study Phase: Phase 1
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drugs: MK-3475, Gemcitabine
Study Phase: Phase 1/Phase 2
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug, Other
Study Drug: High-dose IL-2
Study Phase: Phase 2
A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer
A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug, Dietary supplement
Study Drugs: Cyclophosphamide, Indomethacin, Omeprazole
Study Phase: Phase 1
Intratumoral Ipilimumab in Head and Neck Cancer
Intratumoral Ipilimumab in Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ipilimumab
Study Phase: Phase 1
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Paclitaxel, Capecitabine
Study Phase: Phase 1/Phase 2
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug, Procedure
Study Drugs: LY2157299, Capecitabine, Fluorouracil
Study Phase: Phase 2
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Bicalutamide
Study Phase: Phase 2
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Radiation, Biological
Study Drug: High Dose IL-2
Study Phase: Phase 2
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Drug, Procedure
Study Drug: MEDI6469 Anti-OX40 Antibody
Study Phase: Phase 1
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug
Study Drugs: Galactoarabino-Rhamnogalactouronate, Pembrolizumab
Study Phase: Phase 1
Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer
Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drug: MEDI6469
Study Phase: Phase 1
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
Enrollment Status: Unknown
Publish Date: September 16, 2020
Intervention Type: Device
Study Phase: Not Applicable
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
A Pilot Study of DPV-001 DRibble Vaccine With Imiquimod in Advanced Prostate Cancer
A Pilot Study of DPV-001 DRibble Vaccine With Imiquimod in Advanced Prostate Cancer
Enrollment Status: Completed
Publish Date: October 11, 2018
Intervention Type: Drug, Biological
Study Phase: Phase 1
A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy
A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy
Enrollment Status: Completed
Publish Date: August 29, 2018
Intervention Type: Genetic, Procedure
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Enrollment Status: Completed
Publish Date: August 17, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer
Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: August 17, 2018
Intervention Type: Drug
Study Phase: Phase 1
Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC
Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC
Enrollment Status: Completed
Publish Date: July 06, 2017
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 22 Less Clinical Trials

66 Total Publications

Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System.
Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System.
Journal: JCO oncology practice
Published: November 12, 2024
Similar Doctors
Hagen F. Kennecke
Elite in Neuroendocrine Tumor
Dr. Hagen F. Kennecke
Oncology | Hematology Oncology
Elite in Neuroendocrine Tumor
Dr. Hagen F. Kennecke
Oncology | Hematology Oncology

University Professional Services

1130 Nw 22nd Ave, Suite 150, 
Portland, OR 
 (4.0 miles away)
971-262-9600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hagen Kennecke is an Oncologist and a Hematologist Oncology provider in Portland, Oregon. Dr. Kennecke is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Carcinoid Syndrome. Dr. Kennecke is currently accepting new patients.

Distinguished in Neuroendocrine Tumor
Dr. Guillaume J. Pegna
Oncology
Distinguished in Neuroendocrine Tumor
Dr. Guillaume J. Pegna
Oncology

University Professional Services

3303 S Bond Ave, 
Portland, OR 
 (3.4 miles away)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Guillaume Pegna is an Oncologist in Portland, Oregon. Dr. Pegna is rated as an Advanced provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Pancreatic Cancer, and Familial Pancreatic Cancer. Dr. Pegna is currently accepting new patients.

Distinguished in Neuroendocrine Tumor
Dr. Kevin W. Yee
Hematology | Hematology Oncology | Oncology
Distinguished in Neuroendocrine Tumor
Dr. Kevin W. Yee
Hematology | Hematology Oncology | Oncology

University Professional Services

15700 Sw Greystone Ct, 
Beaverton, OR 
 (10.9 miles away)
503-494-3442
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin Yee is a Hematologist and a Hematologist Oncology provider in Beaverton, Oregon. Dr. Yee is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Yee is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Urba's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile